Catherine Bomont

Title: Catherine Bomont: Innovator in Neurological Treatments

Introduction

Catherine Bomont is a notable inventor based in Bridgewater, NJ (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for dopamine-related neurological disorders. Her work is characterized by a commitment to advancing medical science and improving patient outcomes.

Latest Patents

Catherine holds a patent for "3-piperidinylisochroman-5-ols as dopamine agonists." This invention provides compounds of formula I, which includes a stereoisomer or a pharmaceutically acceptable salt thereof. The patent outlines a method for treating various dopamine-related neurological disorders, including psychological, cardiovascular, cognitive, and attention disorders, as well as substance abuse and addictive behavior. The treatment involves administering a therapeutically effective amount of the compounds to patients in need.

Career Highlights

Catherine is currently associated with Aventis Pharmaceuticals Inc., where she continues to innovate and contribute to the pharmaceutical industry. Her work has been instrumental in developing new therapeutic approaches that address complex neurological conditions.

Collaborations

Catherine has collaborated with notable colleagues such as Gregory Shutske and Keith John Harris. These partnerships have enhanced her research and development efforts, leading to advancements in the field.

Conclusion

Catherine Bomont's contributions to the pharmaceutical industry, particularly in the area of neurological treatments, highlight her role as an influential inventor. Her innovative work continues to pave the way for new therapeutic options for patients suffering from dopamine-related disorders.